16,217 Shares in Sanofi $SNY Acquired by Gibbs Wealth Management

Posted by Francis Steltz on Jul 25th, 2026

Gibbs Wealth Management purchased a new position in Sanofi (NASDAQ:SNY – Free Report) in the 1st quarter, Holdings Channel reports. The institutional investor purchased 16,217 shares of the company’s stock, valued at approximately $781,000.

A number of other institutional investors have also added to or reduced their stakes in SNY. Raymond James Financial Inc. raised its position in shares of Sanofi by 81.3% during the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after buying an additional 2,635,867 shares during the last quarter. Capital Research Global Investors purchased a new position in shares of Sanofi in the fourth quarter worth $79,960,000. Morgan Stanley boosted its position in shares of Sanofi by 20.4% during the fourth quarter. Morgan Stanley now owns 9,102,196 shares of the company’s stock worth $441,093,000 after acquiring an additional 1,540,271 shares during the last quarter. Manning & Napier Advisors LLC boosted its position in shares of Sanofi by 728,134.8% during the first quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company’s stock worth $57,542,000 after acquiring an additional 1,194,141 shares during the last quarter. Finally, Franklin Resources Inc. grew its stake in Sanofi by 29.7% during the fourth quarter. Franklin Resources Inc. now owns 5,100,097 shares of the company’s stock valued at $247,151,000 after acquiring an additional 1,168,339 shares in the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Price Performance

Sanofi stock opened at $43.35 on Friday. Sanofi has a 52-week low of $40.89 and a 52-week high of $52.68. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. The firm’s fifty day moving average is $43.44 and its 200 day moving average is $45.36. The company has a market cap of $105.10 billion, a price-to-earnings ratio of 12.11, a PEG ratio of 1.10 and a beta of 0.34.

Analysts Set New Price Targets

SNY has been the topic of a number of research reports. Wall Street Zen downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Saturday, July 18th. Citigroup reissued a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Morgan Stanley set a $49.00 price objective on Sanofi in a research report on Wednesday, July 8th. BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price on the stock. in a report on Monday, April 20th. Finally, Argus upgraded Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $49.50.

View Our Latest Stock Analysis on Sanofi

Sanofi Profile

(Free Report)

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.